Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa

Sponsor
Holdsworth House Medical Practice
Study ID
NCT05040698
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

A 16 week exploratory, Proof of Concept study to evaluate the effect of Fostamatinib (12 weeks of treatment) upon cutaneous inflammation in Hidradenitis Suppurativa.

Key Dates

Start date
Oct 1, 2021
Status verified
Feb 2023
Primary completion
Jan 13, 2023
Completion
Jan 27, 2023

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open Label Fostamatinib
    Open label Fostamatinib 100mg dose adjusted by the Principal Investigator after week 1

Primary Outcome Measure

Week 4 evaluation [ Time Frame: 4 weeks ]

Related Studies